Safety, efficacy, and time to clinical response with bevacizumab plus FOLFIRI regimen in metastatic colorectal cancer

被引：0
|
作者：
Tomao, S., Sr. [1 ,2 ,3 ,4 ]
Spinelli, G. [1 ,2 ,3 ,4 ]
Rossi, L. [1 ,2 ,3 ,4 ]
Pasciuti, G. [1 ,2 ,3 ,4 ]
Arcangeli, G. [1 ,2 ,3 ,4 ]
D'Aprile, M. [1 ,2 ,3 ,4 ]
Veltri, E. [1 ,2 ,3 ,4 ]
Baiano, G. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Roma La Sapienza, Rome, Italy
[2] SM Goretti Gen Hosp, Latina, Italy
[3] Gen Hosp, Gaeta, Italy
[4] Gen Hosp, Fondi, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15138
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer
    Degirmenci, M.
    Karaca, B.
    Gorumlu, G.
    Durusoy, R.
    Piskin, G. Demir
    Bozkurt, M. T.
    Cirak, Y.
    Tunali, D.
    Karabulut, B.
    Sanli, U. A.
    Uslu, R.
    MEDICAL ONCOLOGY, 2010, 27 (03) : 585 - 591
  • [2] Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer
    M. Degirmenci
    B. Karaca
    G. Gorumlu
    R. Durusoy
    G. Demir Piskin
    M. T. Bozkurt
    Y. Cirak
    D. Tunali
    B. Karabulut
    U. A. Sanli
    R. Uslu
    Medical Oncology, 2010, 27 : 585 - 591
  • [3] Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer
    Tomoyasu Yoshihiro
    Hitoshi Kusaba
    Akitaka Makiyama
    Kazuma Kobayashi
    Masato Uenomachi
    Mamoru Ito
    Yasuhiro Doi
    Kenji Mitsugi
    Tomomi Aikawa
    Kotoe Takayoshi
    Taito Esaki
    Hozumi Shimokawa
    Kenji Tsuchihashi
    Hiroshi Ariyama
    Koichi Akashi
    Eishi Baba
    International Journal of Clinical Oncology, 2019, 24 : 508 - 515
  • [4] Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer
    Yoshihiro, Tomoyasu
    Kusaba, Hitoshi
    Makiyama, Akitaka
    Kobayashi, Kazuma
    Uenomachi, Masato
    Ito, Mamoru
    Doi, Yasuhiro
    Mitsugi, Kenji
    Aikawa, Tomomi
    Takayoshi, Kotoe
    Esaki, Taito
    Shimokawa, Hozumi
    Tsuchihashi, Kenji
    Ariyama, Hiroshi
    Akashi, Koichi
    Baba, Eishi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) : 508 - 515
  • [5] Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study
    Strickler, John H.
    Cubillo, Antonio
    Liang, Jin-Tung
    Matrana, Marc
    Kozloff, Mark
    Lowe, Thomas
    Blaney, Martha
    Sahtout, Mohammad
    Naumovski, Louie
    Wainberg, Zev A.
    FUTURE ONCOLOGY, 2022, 18 (27) : 3011 - 3020
  • [6] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Gorbunova, Vera
    Beck, J. Thaddeus
    Hofheinz, Ralf-Dieter
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    Mangel, Laszlo
    Fernandez, Elena Elez
    Deming, Dustin A.
    Ramanathan, Ramesh K.
    Torres, Alison H.
    Sullivan, Danielle
    Luo, Yan
    Berlin, Jordan D.
    BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 183 - 189
  • [7] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Vera Gorbunova
    J. Thaddeus Beck
    Ralf-Dieter Hofheinz
    Pilar Garcia-Alfonso
    Marina Nechaeva
    Antonio Cubillo Gracian
    Laszlo Mangel
    Elena Elez Fernandez
    Dustin A. Deming
    Ramesh K. Ramanathan
    Alison H. Torres
    Danielle Sullivan
    Yan Luo
    Jordan D. Berlin
    British Journal of Cancer, 2019, 120 : 183 - 189
  • [8] Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer
    Kim, Ji-Won
    Lee, Keun-Wook
    Kim, Kyu-Pyo
    Lee, Ju Hyun
    Hong, Yong Sang
    Kim, Jeong-Eun
    Kim, Sun Young
    Park, Sook Ryun
    Nam, Byung-Ho
    Cho, Sang-Hee
    Chung, Ik-Joo
    Park, Young Suk
    Oh, Ho-Suk
    Lee, Myung-Ah
    Kang, Hye Jin
    Park, Young Iee
    Song, Eun-Kee
    Han, Hye Sook
    Lee, Kyu Taeg
    Shin, Dong Bok
    Kang, Jung Hun
    Zang, Dae Young
    Kim, Jee Hyun
    Kim, Tae Won
    ONCOLOGIST, 2017, 22 (03): : 293 - 303
  • [9] Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
    Gorbunova, Vera
    Beck, Thaddeus
    Hofheinz, Ralf
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Safety and Efficacy of Bevacizumab plus Concurrent Chemoradiotherapy for Recurrent or Metastatic Colorectal Cancer
    Li, Y.
    Zhu, X.
    Li, X.
    Shi, C.
    Geng, J.
    Zhang, Y.
    Cai, Y.
    Wang, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E11 - E12
12345